Clinical trial
Recombinant CMV gB Vaccine in Postpartum Women
NCT00125502 · Robert Pass, MD, Other · Completed
Key facts
| NCT number | NCT00125502 |
|---|---|
| Title | Recombinant CMV gB Vaccine in Postpartum Women |
| Official title | A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Recombinant CMV gB Vaccine in Postpartum Women |
| Lead sponsor | Robert Pass, MD, Other |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH MCM Vaccines B.V. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Biological, Drug |
| Interventions | CMV gB vaccine, MF59 adjuvant, Placebo |
| Enrollment | 464 |
| Start date | Aug 1, 1999 |
| Primary completion | Jun 1, 2007 |
| Completion | Jan 1, 2010 |
| First posted | Aug 1, 2005 |
| Last update posted | Sep 20, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: